CN101254208A - Combination for curing alopecia - Google Patents
Combination for curing alopecia Download PDFInfo
- Publication number
- CN101254208A CN101254208A CNA2008100650254A CN200810065025A CN101254208A CN 101254208 A CN101254208 A CN 101254208A CN A2008100650254 A CNA2008100650254 A CN A2008100650254A CN 200810065025 A CN200810065025 A CN 200810065025A CN 101254208 A CN101254208 A CN 101254208A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- alopecia
- 60mug
- ferrum
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for treating alopecia, belonging to the technology field of medicines. The composition comprises vitamin A 2,500-3,500IU, vitamin B1 2-3mg, vitamin B2 2-3mg, vitamin B6 0.2-0.3mg, vitamin B12 40-60Mug, vitamin D2 250-350IU, vitamin E 4-6mg, nicotinamide 7-8mg, calcium pantothenate 2-3mg, choline bitartrate 20-30mg, inositol 20-30mg, ferrum 4-6mg, iodine 40-60Mug, manganese 0.4-0.6, zinc 0.2-0.3mg, calcium hydrogen phosphate 270-280mg, magnesium 0.4-0.6mg, potassium 4-6mg, and L-lysine 10-15mg. The inventive composition can be made into tablet, capsule or oral liquid; and has the advantages of synergic action of each component, good therapeutic effect, low toxic and side effects, applicability to long-term administration, and convenience for administration and carrying.
Description
Technical field
The present invention relates to treat the medicine of alopecia, relate in particular to a kind of compositions for the treatment of alopecia.
Background technology
Alopecia areata is the alopecia of a kind of common pathological the most, is a kind of alopecia circumscripta of unexpected generation, and illing skin is normal, NIP, and smooth surface is the alopecia of speckle shape, sustainable several months or several years, most can regeneration.The speckle that comes off can be 1～2 place, place surplus many persons have 10, and the whole head hair of severe patient comes off rapidly, is called alopecia totalis.To the treatment of alopecia areata, modal is to adopt the mode of external or Chinese medicine for oral administration to carry out.Although the medicine of multiple treatment usefulness is arranged on the market, there are defectives such as undesirable such as effect, that side effect is big in therapeutic effect.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, provide a kind of therapeutic effect good, the pharmaceutical composition of the treatment alopecia that side effect is little.
For achieving the above object, the technical solution used in the present invention is:
A kind of compositions for the treatment of alopecia is characterized in that: comprise vitamin A, vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin D
2, vitamin E, nicotiamide, calcium pantothenate, adipokinetic hormone, inositol, ferrum, iodine, manganese, zinc, calcium hydrogen phosphate, magnesium, potassium and L-lysinate, each component according to above-mentioned order in following ratio proportioning: 2500～3500IU: 2～3mg: 2～3mg: 0.2～0.3mg: 40～60 μ g: 250～350IU: 4～6mg: 7～8mg: 2～3mg: 20～30mg: 20～30mg: 4～6mg: 40～60 μ g: 0.4～0.6mg: 0.2～0.3mg: 270～280mg: 0.4～0.6mg: 4～6mg: 10～15mg.
In a kind of optimized technical scheme, each component according to above-mentioned order in following ratio proportioning: 3000IU: 2.5mg: 2.5mg: 0.25mg: 50 μ g: 300IU: 5mg: 7.5mg: 2.5mg: 25mg: 25mg: 5mg: 50 μ g: 0.5mg: 0.25mg: 279mg: 0.5mg: 5mg: 12.5mg.
Each component is mixed in proportion, adds suitable pharmaceutical excipient or carrier again and promptly can be made into appropriate formulation.
Beneficial effect of the present invention: each component coordinated, therapeutic effect is good; Toxic and side effects is little, can take for a long time; Can be made into tablet, capsule or oral liquid etc., conveniently take and carry.
The specific embodiment
Among the present invention, vitamin B
12Bring into play major function in compositions, its effect is, transforms the back through human body and forms medullary layer and hair follicle, reconfigures to make hair follicle atrophy position obtain again nourishing, and stimulates the circulation of medullary layer simultaneously, makes it deciliter freely.
Vitamin A and D synergism, major function is the integrity of supplementary table layer tissue, allows the epidermal area that comes to harm obtain repairing.This two kinds of vitamin and vitamin B
12Combine, make hair follicle, medullary layer and epidermal area obtain combination again, make hair regrow out.
Other vitamin and trace element, the performance miscellaneous function, the main basic role that supports body and body that rises transforms the back through health and arrives each fulcrum, makes health obtain required replenishing and repairing.
Below with embodiment the present invention is described, but embodiment does not constitute any limitation of the invention.
Embodiment 1
With vitamin A, vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin D
2, vitamin E, nicotiamide, calcium pantothenate, adipokinetic hormone, inositol, ferrum, iodine, manganese, zinc, calcium hydrogen phosphate, magnesium, potassium and L-lysinate be in 3000IU: 2.5mg: 2.5mg: 0.25mg: 50 μ g: 300IU: 5mg: 7.5mg: 2.5mg: 25mg: 25mg: 5mg: the ratio of 50 μ g: 0.5mg: 0.25mg: 279mg: 0.5mg: 5mg: 12.5mg is mixed, sneak into adjuvant such as amylum pregelatinisatum again, fully stir and make its mix homogeneously, make sheet by every amount that contains 3000IU vitamin A and other component according to the above ratio with tablet machine.
Embodiment 2
With vitamin A, vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin D
2, vitamin E, nicotiamide, calcium pantothenate, adipokinetic hormone, inositol, ferrum, iodine, manganese, zinc, calcium hydrogen phosphate, magnesium, potassium and L-lysinate be in 2500IU: 2mg: 2mg: 0.20mg: 40 μ g: 250IU: 4mg: 7mg: 2mg: 20mg: 20mg: 4mg: the ratio of 40 μ g: 0.4mg: 0.20mg: 270mg: 0.4mg: 4mg: 10mg is mixed, sneak into adjuvant such as amylum pregelatinisatum again, fully stir and make its mix homogeneously, make sheet by every amount that contains 2500IU vitamin A and other component according to the above ratio with tablet machine.
Embodiment 3
With vitamin A, vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin D
2, vitamin E, nicotiamide, calcium pantothenate, adipokinetic hormone, inositol, ferrum, iodine, manganese, zinc, calcium hydrogen phosphate, magnesium, potassium and L-lysinate be in 3500IU: 3mg: 3mg: 0.30mg: 60 μ g: 350IU: 6mg: 8mg: 3mg: 30mg: 30mg: 6mg: the ratio of 60 μ g: 0.6mg: 0.30mg: 280mg: 0.6mg: 6mg: 15mg is mixed, sneak into adjuvant such as amylum pregelatinisatum again, fully stir and make its mix homogeneously, make sheet by every amount that contains 3500IU vitamin A and other component according to the above ratio with tablet machine.
Embodiment 4 acute toxicity tests
Select 300 Kunming white mice, body weight 20 ± 1g, be divided into three groups at random, to the tablet of every group of difference gastric infusion embodiment 1～3, a week is observed in 1 of administration every day continuously, do not find any mice dying and obvious toxic and side effects, being equivalent to the people intends belonging to nontoxic substantially with clinical dosage (2/40kg, body weight for humans is in average 40kg) 1000 times.
Embodiment 5 chronic toxicity tests
Select 300 rat, the children Mus, body weight 6 ± 1g, be divided into three groups at random, to the tablet of every group of difference gastric infusion embodiment 1～3,0.1 of administration every day, gastric infusion is six months continuously, test shows that rat growth promoter and daily behavior are not had obvious influence, and blood, organ, tissue and system are not had obvious damage.This test shows that compositions of the present invention application safety within a certain period of time is reliable, no obvious toxic-side effects.
Embodiment 6 clinical trials
Certain person, 30 years old, alopecia areata, the about 1 yuan of coin-size in alopecia position is taken the medicine among the embodiment 1, takes 1 at every turn, takes drug withdrawal after month every day twice, and the alopecia position grows New Development, about 50 days of trophophase.
Claims (2)
1. a compositions for the treatment of alopecia is characterized in that: comprise vitamin A, vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin D
2, vitamin E, nicotiamide, calcium pantothenate, adipokinetic hormone, inositol, ferrum, iodine, manganese, zinc, calcium hydrogen phosphate, magnesium, potassium and L-lysinate, each component according to above-mentioned order in following ratio proportioning: 2500～3500IU: 2～3mg: 2～3mg: 0.2～0.3mg: 40～60 μ g: 250～350IU: 4～6mg: 7～8mg: 2～3mg: 20～30mg: 20～30mg: 4～6mg: 40～60 μ g: 0.4～0.6mg: 0.2～0.3mg: 270～280mg: 0.4～0.6mg: 4～6mg: 10～15mg.
2. the compositions of treatment alopecia according to claim 1 is characterized in that: each component according to above-mentioned order in following ratio proportioning: 3000IU: 2.5mg: 2.5mg: 0.25mg: 50 μ g: 300IU: 5mg: 7.5mg: 2.5mg: 25mg: 25mg: 5mg: 50 μ g: 0.5mg: 0.25mg: 279mg: 0.5mg: 5mg: 12.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100650254A CN101254208A (en) | 2008-01-04 | 2008-01-04 | Combination for curing alopecia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100650254A CN101254208A (en) | 2008-01-04 | 2008-01-04 | Combination for curing alopecia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101254208A true CN101254208A (en) | 2008-09-03 |
Family
ID=39889532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100650254A Pending CN101254208A (en) | 2008-01-04 | 2008-01-04 | Combination for curing alopecia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101254208A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053622A (en) * | 2015-07-29 | 2015-11-18 | 邓克统 | Blue peacock dedicated feed and preparation method thereof |
| CN105878277A (en) * | 2016-02-29 | 2016-08-24 | 孙文觉 | Oral vitamin capsules for promoting hair growth and beautifying hair |
| CN111713690A (en) * | 2020-06-26 | 2020-09-29 | 上海复旦奥医医学科技有限公司 | Special medical nutrition formula food for alopecia and preparation method thereof |
| CN112655969A (en) * | 2021-03-15 | 2021-04-16 | 江苏艾兰得营养品有限公司 | Choline bitartrate granules, tablets containing same and preparation method |
-
2008
- 2008-01-04 CN CNA2008100650254A patent/CN101254208A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053622A (en) * | 2015-07-29 | 2015-11-18 | 邓克统 | Blue peacock dedicated feed and preparation method thereof |
| CN105878277A (en) * | 2016-02-29 | 2016-08-24 | 孙文觉 | Oral vitamin capsules for promoting hair growth and beautifying hair |
| CN111713690A (en) * | 2020-06-26 | 2020-09-29 | 上海复旦奥医医学科技有限公司 | Special medical nutrition formula food for alopecia and preparation method thereof |
| CN112655969A (en) * | 2021-03-15 | 2021-04-16 | 江苏艾兰得营养品有限公司 | Choline bitartrate granules, tablets containing same and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
| KR102093872B1 (en) | Injection Composition For Fat Reduction and method of manufacturing the same | |
| RU2509569C2 (en) | Composition for treating and preventing osteoarthritis and osteoarthrosis | |
| CN1391464A (en) | Formulation for menopausal women | |
| HRP20121072T1 (en) | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring | |
| CN1997353A (en) | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy | |
| KR20210124113A (en) | Composition for maintaining effect of filler | |
| CN101254208A (en) | Combination for curing alopecia | |
| CN101283797A (en) | Health products for promoting the intelligence and strengthening the brain using walnut oil as matrix | |
| CN104905277A (en) | Composition with functions of improving skin moisture, elasticity and wrinkles | |
| CN100515430C (en) | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D | |
| CA2528312C (en) | Methods of managing the symptoms of premenstrual syndrome | |
| ES2282880T3 (en) | METHOD TO TREAT OR PREVENT CHRONIC WOUNDS AND COMPLETE NUTRITIVE COMPOSITION UNDERSTANDING GLYCIN AND / OR LEUCINE TO USE IN THIS. | |
| Richardson et al. | Branched chain amino acid treatment of tardive dyskinesia in children and adolescents | |
| CN101085076B (en) | Chinese and Western medicine united sustained-release injection for preventing and controlling coccidiosis of rabbit and its preparation method | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JP2009062318A (en) | Hair-growing agent kit and method for growing hair | |
| Schlappner et al. | Acute Papulopustular Acne: Associated With Prolonged Intravenous Hyperalimentation | |
| US10792320B2 (en) | Methods for treatment of bladder dysfunction | |
| CN106362141A (en) | Safe and multi-effect freckle removing agent and preparation method thereof | |
| RU2220712C1 (en) | Agent and set for normalization of functional disorders arising in preclimacteric and climacteric period | |
| CA2325033C (en) | Use of ribose to treat fibromyalgia | |
| Zuikina et al. | Research on the composition development and phyto-ointment technology for complex mastopathy therapy | |
| Gafni et al. | A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1) | |
| CN1263392C (en) | Egg with face nursing and nourishing function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080903 |